NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
Clinical Trials
8 trialsNCT03913234 2022-05-10
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Phase 1/2 Unknown
NCT04888663 2021-05-21
Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)
Yonsei University
Phase 1/2 Unknown
NCT04170595 2021-03-03
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
Genor Biopharma Co., Ltd.
Phase 1/2 Unknown
NCT03994107 2020-01-22
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Peking Union Medical College
Phase 1/2 Unknown
NCT04152057 2019-11-05
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
West China Hospital
Phase 1/2 Unknown
NCT02030561 2016-06-22
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT02805829 2016-06-22
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
Xuzhou Medical University
Phase 1/2 Unknown